Zoledronic acid

Drug Profile

Zoledronic acid

Alternative Names: Aclasta; AK-156; CGP-42446A; Reclast; ZOL-446; zoledronate; Zometa

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Asahi Kasei Pharma Corp; Novartis; UNICANCER
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone metastases; Corticosteroid-induced osteoporosis; Fracture; Male osteoporosis; Malignant hypercalcaemia; Mesothelioma; Multiple myeloma; Osteitis deformans; Postmenopausal osteoporosis
  • Registered Osteoporosis
  • Phase II Breast cancer
  • Discontinued Osteogenesis imperfecta; Osteosarcoma; Rheumatoid arthritis

Most Recent Events

  • 19 Jun 2017 Novartis completes a phase II trial in Osteoporosis (Prevention) in Australia (IV) (ACTRN12607000596404)
  • 28 Sep 2016 Registered for Osteoporosis in Japan (IV)
  • 16 Sep 2016 Pharmacokinetics, pharmacodynamics and adverse events data from a clinical trial in Osteoporosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top